105 results about "Asthma treatment" patented technology

The present invention provides methods for the assessment, diagnosis, or prognosis of asthma including methods for providing an assessment, diagnosis, or prognosis comprising the step of exposing a sample derived from a patient to an allergen in vitro. The present invention also provides methods for selecting, as well as evaluating the effectiveness of, asthma treatments. The markers of the present invention can be used in methods to identify or evaluate agents capable of modulating marker expression levels in subjects with asthma

The present invention relates to compounds of formula (I):wherein R1 is C1-6alkylamino, C1-6alkoxy, or C3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.

The invention relates to an oral preparation of asthma-relieving decoction which is prepared by ginkgo seeds and other eight Chinese medicines mainly for asthma treatment and the preparation method thereof; according to conventional processes, the invention is prepared by mixed tracts (extractum or dry powders and volatile oils), which are utilized as raw materials and formed by ginkgo seeds, ephedra, perilla fruits, coltsfoot flowers, almond, cortex mori, scutellaria, pinellia ternate and glycyrrhiza, together with the vectors or the excipient, which are utilized as matrix and acceptable in pharmacy. The preparation has the efficacies of ventilating lung, lowering qi, clearing away heat and eliminatingsputum and mainly treats wind and cold affecting superficies and ashma causing accumulation of phlegm-heat. The long-term clinical application shows that the oral preparation has a very good therapeutic effects on bronchial asthma and chronic bronchial asthma, etc.

The present invention relates to compounds of formula (I):wherein R1 is C1-6alkylamino, C1-6alkoxy, or C3-7cycloalkyloxy; m is an integer having a value of 2 to 6; R2 is hydrogen, C1-6alkyl, or C3-7cycloalkylC0-6alkyl; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.

Methods for diagnosing, monitoring and evaluating asthma control in subjects and methods of monitoring the efficacy of asthma treatment regimes in said subjects using blood levels of α-tocopherol quinone.

The invention provides application of anhydroicaritin in preparation of drugs used for treating asthma, which belongs to the field of medicine. Anhydroicaritin is a Chinese herbal monomer extracted from the traditional Chinese medicine epimedium; when used for treating asthma, anhydroicaritin can substantially reduce total IgE content in the serum of a patient with asthma and the rates of IL-4, IFN-r and eosinophilic granulocytes in the pulmonary alveoli of the patient, and anhydroicaritin has a better treatment effect on the patient with asthma compared with those of an epimedium extract and icariin. Anhydroicaritin has the advantages of comprehensive effects, small side effects and wide clinical application prospects when used for treatment of asthma.

The present invention relates to methods of asthma treatment and prevention using αvβ6 antagonists, such as αvβ6-binding antibodies. In particular, the invention relates to the discovery of a correlation between reduced expression of αvβ6 and the protection from the increase in airway sensitivity seen in chronic allergen-challenged mice. This protection is associated with protection from the usual allergen-induced increase in airway epithelial mast cells.

The invention provides a manual dry power inhaler (PP-DPI) which can treat asthma by inhaling medicines. The manual dry powder inhaler includes an air flow chamber which can inhale air from an air inlet channel, allow medicine to keep a fine power shape, form a starting part of an air channel, generate turbulent flow while the air passes through the air flow chamber to allow vibration of a medicine housing inhaled the air flow chamber, and release the medicines contained in the medicine housing; (2) a positive pressure air feeding device of a manual switch which is connected to the air flow chamber, and can trigger and push the power to flow to a contact throat through the air channel; (3) a sealing mechanism which can close the air flow chamber to form the air channel; (4) a sharp article which is arranged in the air flow chamber and can puncture the medicine housing and then release the medicines to the air channel; (5) an air discharging channel which is connected to the air flow chamber; (6) the contact throat which can form a part of the air channel, wherein the medicines can be supplied to a patient through the contact throat; (7) an optional gasket which is connected to the contact throat and facilitates inhalation of the medicines; and (8) a dosage bag having dry powder-shape medicine active ingredients capable of treating the asthma.

The invention discloses a bronchial asthma treatment drug pillow and belongs to the traditional Chinese medicine technical field. The bronchial asthma treatment drug pillow is formed by the following raw materials of, almonds, dried tangerine or orange peel, platycodon root, honeysuckle, mint, ephedra, cloves, herba periliae, cynanchum glaucescens, ageratum, plaster stone, chrysanthemum, as arum and licorice. According to the bronchial asthma treatment drug pillow, the drug can directly act on the head, the lung can be dispersed, the phlegm can be reduced, the cough can be relieved, and accordingly the effects of lung dispersing, phlegm and pus elimination, spleen and stomach warming for cold dispelling and meridian activating for pain stopping are achieved; the bronchial asthma treatment drug pillow is suitable for the chronic bronchial asthma and the effects on the acute bronchial asthma and bronchitis are also achieved; meanwhile various disadvantages and side effects caused by the traditional treatment method are avoided and the asthma treatment effective rate reaches 98%.

The invention discloses a ledebouriella root / smoked plum composition for treating asthma and applications of the composition. The medicine provided by the invention can effectively improve the curative effects of asthma treatment.

Disclosed are novel substituted amino triazoles of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of Formula (I) are inhibitors of Acidic mammalian chitinase (AMCase) and are useful, in a non-limiting example, for treating asthma. Also provided are pharmaceutical compositions containing at least one compound of the present invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier, solvent, adjuvant or diluent, and methods of using such compounds and / or compositions to treat asthma and / or to monitor asthma treatment.

The present invention relates to the use of a composition comprising a fixed combination of a) formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and b) beclometasone dipropionate; for the manufacture of a medicament for use in the prevention and / or treatment of an exacerbation of asthma, intermittent asthma and / or episodes in chronic asthma during the maintenance therapy of asthma with the same composition for symptomatic relief, when needed.

The invention discloses a cough relieving ginkgo biscuit. The cough relieving ginkgo biscuit comprises, by weight, 65-75 parts of wheat, 50-60 parts of sticky rice, 30-35 parts of kudzu vine root, 20-25 parts of black garlic, 1-3 parts of madder, 2-3 parts of eclipta, 1-2 parts of oldenlandia diffusa, 1-2 parts of saffron crocus, 20-25 parts of red kojic rice, 25-30 parts of lobster shell, 30-40 parts of ginkgo, 1-2 parts of food additive, and a proper amount of water. According to the cough relieving ginkgo biscuit, the wheat and the sticky rice serve as main materials, and the good nutrition and nourishing effects are achieved. The ginkgo is particularly added, and the good medical effect and the good dietary therapy effect on lung qi profiting, cough and asthma treatment, astringency inducting and leucorrhoea arresting, xeransis and blood vessel protection are achieved. The cough relieving ginkgo biscuit can further have the functions of nourishing yin, beautifying, being resistant to aging, expanding micro-vessels, promoting blood circulation, enabling persons to have flushing complexion and be in high spirit, prolonging life, eliminating phlegm and relieving asthma.

The invention provides a method for constructing an asthmatic animal model. The method comprises the following steps: grinding 15-20g of fresh silkworm chrysalis into powder with liquid nitrogen; adding 25ml of PBS (phosphate buffer solution) to wash silkworm protein, and grinding the silkworm protein for 1-2 hours in a homogenizer; taking out the silkworm protein in the homogenizer, and centrifuging at 4 DEG C at 8,000rpm for 15 minutes; repeatedly centrifuging supernatant for three times; assaying whether protein concentration reaches standard or not by adopting a BCA (bicinchoninic acid) method to obtain the silkworm protein. The silkworm protein is applied to a Babl / c mouse at 5-6 weeks, injecting 50mu g of silkworm protein into a mouse in an intraperitoneal manner, and adding 4mg of aluminum hydroxide for sensitization once a week, and continuously performing intraperitoneal injection for three weeks; continuously exciting for 1 week (50mu g of silkworm crude protein is inhaled in a nasal manner for a mouse) after the last time of sensitization; performing airway hyperreactivity assay and pathological examination in 24 hours after nasal inhalation in the last day. According to the method, the problem of asthmatic animal model construction difficulty can be solved, and the animal model is stable and controllable and can be used for studying asthma pathogenesis and curative effect evaluation of asthma treatment medicaments.

The invention relates to the technical field of drugs for treating an asthma disease and relates to a drug for treating the asthma disease and a preparation method thereof. The drug for treating the asthma disease is prepared according to the method which comprises the following steps of: uniformly mixing sorbus tianchanica extractum powder and an auxiliary material in a weight ratio of 1:1 to 3:1 to obtain a mixed material; adding 85-95vol% of ethanol as a wetting agent to the mixed material. The drug disclosed by the invention is based on the abundant resources of a folk peculiar natural plant drug-sorbus tianchanica with definite asthma treatment pharmacological action in Sinkiang, takes the advantages of national traditional medicines and folk traditional medicines especially, is prepared according to a modern advanced pharmaceutical technology by steps of adding the wetting agent to the sorbus tianchanica extractum powder and the auxiliary material, granulating through a wet method, drying and refining granules. The drug has definite treatment effect, stable and controllable quality, high safety and low toxicity, is convenient to use, and can be put into industrial production so as to reduce the production cost.

The invention discloses application of PD-1H agonists to preparing medicine compositions for preventing or treating asthma of objects. The application has the advantages that treatment is carried out by the aid of agonist type PD-1H monoclonal antibodies, accordingly, the quantities of inflammatory cells (eosinophil and lymphocyte in particular) in mouse BALF (bronchoalveolar lavage fluid) are obviously reduced, pulmonary inflammation and myxopoiesis are obviously reduced, and accordingly the fact that PD-1H can be targeted for treating allergic diseases is indicated by results.

The invention provides application of a Fructus Aurantii Immaturus total flavonoid extract in preparation of a drug treating bronchial asthma. Experimental results show that the extract can be used for treating bronchial asthma, and the Fructus Aurantii Immaturus total flavonoid extract can substantially reduce the duration of bronchial, the proportion of eosinophils and the serum IgE level. The Fructus Aurantii Immaturus total flavonoid extract can improve the inflammatory morphological change of bronchi and lung tissues, has significant differences compared with a model group, and has the characteristics of fewer side effect and effective treatment in the process of bronchial asthma treatment.

The invention discloses an auxiliary device for treating allergic asthma, and effectively solves the problems that a conventional auxiliary device for treating allergic asthma cannot synchronously exercise upper limbs and lower limbs of a patient, so that the exercise of the patient is limited, the exercise amplitude cannot be adjusted in the exercise process, the conventional auxiliary device cannot adapt to exercise of different patients, the back of the patient cannot be knocked and massaged in the exercise process, and the patient often sits for physical exercise to cause aching pain of the buttocks in the prior art. The auxiliarydevice comprises a supporting frame, a sitting plate is fixedly connected to the upper end of the supporting frame, and a supporting plate is fixedly connected to the upper end of the sitting plate. a swing rod capable of swinging up and down is arranged on the rear side of the upper end of the supporting plate, a movable plate is slidably connected to the upper end of the rear portion of the supporting plate, the right end of the movable plate is rotationally connected with the swing rod, the swing rod swings up and down to achieve left-right movement of the movable plate at the upper end of the supporting plate, and a telescopic rod is fixedly connected to the front end of the swing rod.

Methods for the treatment of asthma are provided, which comprise: (a) providing an implantable or insertable medical device that comprises an asthma treatment agent; and (b) inserting or implanting the medical device within the lungs (e.g., the trachea or the bronchial tree) of a patient, whereupon the therapeutic agent is delivered to the patient in an amount effective to reduce or eliminate the symptoms of asthma. Also disclosed herein are medical devices and kits for carrying out such methods.

The invention discloses an application of a polygonin atomizing agent as asthma-treating medicine. Each 1000 ml of polygonin spraying agent comprises 1 g of polygonin, 50 ml of propylene glycol, 1 g of sodium pyrosulfite, and the balance of water. Polygonin is prepared in the atomizing agent for the first time in the invention, and thus, the curative effect of asthma treatment is greatly increased through an administration method of atomizing inhalation. The molecular mass of polygonin is small, and the polygonin has the characteristics of fat solubility and no taste; the polygonin has certain solubility in airway secretion fluid or alveolar fluid, can be quickly absorbed through the membrane of an epithelial cell so as to arrive at a target cell and exert the efficacy for relieving asthma and diminishing inflammation, and is suitably prepared into the atomizing agent without adding more additives; asthma is treated through the administration method of atomizing inhalation, and the curative effect of the polygonin atomizing agent is superior to a peroral dosage form of polygonin. Compared with other various dosage forms, the polygonin atomizing agent effectively saves dosage and manufacturing cost, reduces bad effect on patients, and is beneficial to environment protection.

The invention belongs to the technical field of medicines, and particularly relates to new application of guanosine, in particular to new application of guanosine in preparation of medicines for treating asthma or inhibitors of MAPK, NF-kappa B and STAT3. The invention aims to solve the problem that safer and more effective asthma treatment medicines need to be developed urgently in the prior art.It is found that in an in-vitro THP-1-derived macrophage inflammation model, guanosine inhibits generation of a proinflammatory factor IL-6 by inhibiting activation of MAPK and NF-kappa B; in an asthma mouse model, guanosine reduces OVA-IgE of mouse plasma, reduces generation of IL-4, IL-6 and IL-13, relieves airway high reactivity, and relieves lung tissue cell infiltration, airway inflammationand collagen deposition. In addition, the expression levels of p-p38 MAPK, p-p65 NF-kappa B, p-I kappa B alpha and p-STAT3 proteins in lung tissues of mice in a guanosine treatment group are obviouslylower than those in an asthma model group. Therefore, the invention provides application of guanosine in preparation of a p38 MAPK inhibitor, a p65 NF-kappa B inhibitor, an STAT3 inhibitor or an asthma treatment drug.

The invention discloses application of tetrahydrocurcumin in treating allergic asthma. The therapeutic action of the tetrahydrocurcumin (THC) on allergic asthma is firstly found and proved; from the perspective of immunity, the THC can be beneficial to alleviating nose allergy and itching, inhibiting lung eosinophilic granulocyte infiltration, reducing lung goblet cell grume generation, reducing lung collagen deposition, and inhibiting Th2 cell factor production, can provide beneficial information for clinic disease evaluation, and has a favorable application prospect in asthma treatment.

The invention discloses an asthma treatment medicine and belongs to the field of traditional Chinese medicines. Effective components of the asthma treatment medicine comprise the following raw materials: lodestone, lophatherum gracile, common coltsfoot flower, dried green bamboo shoot, winchia calophylla, gymnadenia conopsea, slender root of Common Monkshood, fruit of purple perilla, fructus gleditsiae, immature bitter orange, akoda pumpkin, salvia chinensis, Chinese wingnut leaf, radix peucedani, human placenta and Japanese white birch bark. The asthma treatment medicine has the effects of relieving asthma to realize sedation and moistening lung to suppress cough, can quickly treat bronchitis, emphysema, asthma and other diseases, is high in efficiency and cure rate, has the characteristics of strict compatibility, quite mild herbal property and remarkable curative effect, is convenient to take, low in cost, easy to ingest, free from toxic and side effects, can treat both symptoms and root causes, and facilitates large-scale popularization in clinic practice.

The purpose of the invention is to provide a Chinese patent medicine of a lung-warming panting-calming granule for treating cold wheezing during bronchial asthma attack phases. Aiming at the problems of single dosage form and insufficient drug effect research for current applications of traditional Chinese medicines in asthma treatment, the lung-warming panting-calming granule is prepared based on a hospital preparation used in our hospital for years, and the effectiveness and safety of the granule are verified through pharmacological research and clinical research.

The invention discloses a production method of a medicinal wine for treating asthma, aiming at providing a decoction which is fast in asthma treatment speed and low in cost. The technical scheme adopted by the invention is as follows: wide asthma, pericarpium citri reticulatae and folium eriobotryae are soaked at a constant temperature by strong wine. The production method of the medicinal wine for treating asthma is operated according to the following steps: (1) selecting wide asthma, pericarpium citri reticulatae and folium eriobotryae as raw materials; (2) placing the cleaned wide asthma slices, pericarpium citri reticulatae and folium eriobotryae in a jar held with the strong wine, and then sealing the opening of the jar; (3) conveying the sealed jar in a cellar and storing; (4) opening the jar after 80-120 days, and filtering by a medicine sieve to obtain the medicinal wine for treating asthma; and (5) hermetically packaging the medicinal wine for treating asthma by a bottle. The technical scheme adopted by the invention is simple and convenient to operate, and the medicinal wine for treating asthma is fast in asthma treatment speed and low in cost.

The present invention relates to compounds of formula (I):wherein R1 is C1-6alkylamino, or C1-6alkoxy; m is an integer having a value of 3, 4, or 5; n is an integer having a value of 0 to 3; p is an integer having a value of 1 or 2 and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.

The invention relates to the technical field of asthma treatment, and discloses an asthma treatment device for respiratory medicine. The device comprises a bottom plate, a wetting box is arranged on the left side of the bottom plate, an air pipe is arranged on the upper portion of the left side wall of the wetting box, the free end of the air pipe is connected to a mask, a bearing seat is arrangedat the top of the wetting box, the bearing seat is rotationally connected to a rotating disc, a rotating shaft is arranged on the front face of the rotating disc, the rotating shaft is rotationally connected to the right end of a supporting rod, the left end of the supporting rod is rotationally connected to a push rod, the left end of the push rod is connected to a piston, and the piston is slidably connected to interior of an air cavity. The invention is applicable to the asthma treatment device. The piston moving left and right is arranged in the air cavity, the air cavity can continuouslyinject fresh air into the wetting box, a user is treated through the fresh air with liquid medicine, air is blown to the user through the device, the user controls breathing according to the runningrhythm of the device, the user is helped to adapt to the normal breathing rhythm, and the treatment effect is improved.

The invention relates to application of a compound pseudoephedrine hydrochloride tablet to preparation of a medicine for treating asthma. The compound pseudoephedrine hydrochloride tablet is prepared from pseudoephedrine hydrochloride, dextromethorphan hydrobromide, diphenhydramine hydrochloride, low-substituted hydroxypropyl cellulose, polyvinylpyrrolidone, magnesium stearate and dextrin; the compound pseudoephedrine hydrochloride tablet is used for relaxing tracheal smooth muscle through blocking an L-shaped calcium channel and a non-selective cation channel and can be used as a novel tracheal dilating medicine for treating diseases including asthma and the like. The compound pseudoephedrine hydrochloride tablet provided by the invention is good in pharmacological action and high in active component safety, and a novel and safe asthma treatment medicine is provided for clinic.

The invention provides a pharmaceutical composition used for treating COPD and bronchial asthma, and a preparation method thereof. The pharmaceutical composition comprises active ingredients and a pharmaceutically-acceptable carrier, wherein the active ingredients comprise formoterol fumarate dihydrate, budesonide and tiotropium bromide hydrate, the weight percentages of formoterol fumarate dihydrate, budesonide and tiotropium bromide hydrate in the pharmaceutical composition are 0.001%-0.4%, 0.02%-4% and 0.005%-0.8%, respectively. The pharmaceutical composition provided by the invention is in a dry powder form and is used for inhalation treatment of patients, and the dry powder inhalant has obviously better characteristics compared with sprays and aerosols, and is convenient to carry and easy to operate; medicines in the dry powder form have better stability at room temperature and less susceptibility to microbial contamination; and the most significant progress of the pharmaceutical composition lies in synchronous entering of the medicine powder into a respiratory tract with spontaneous breathing of a patient, so the purpose of specific medicine delivery to the lung is achieved, and difficult coordination and cooperation in the medicine delivery do not exist.

The invention discloses traditional Chinese medicine for treating bronchial asthma. The traditional Chinese medicine comprises, by weight, 6-8 parts of radix changii, 11-13 parts of prepared licorice root, 10-12 parts of bulbus fritillariae cirrhosae, 5-8 parts of fructus arctii, 2-4 parts of fructus aurantii, 4-5 parts of cortex lycii, 6-7 parts of white atractylodes rhizome, 2-4 parts of semen lepidii, 5-8 parts of earthworm, 5-6 parts of herba lysimachiae, 4-6 parts of loofah roots, 2-4 parts of radix platycodonis, 1-3 parts of radix salviae miltiorrhizae, 5-8 parts of prepared RHIZOMA PINELLIAE with juice of rhizima zingiberis rec-ens, 2-4 parts of fructus rubi, 1-3 parts of ephedra herb, 5-8 parts of tribulus terrestris, 2-4 parts of fructus schisandrae chinensis, 2-4 parts of rhizoma polygonati, 1-3 parts of torricellia angulata flowers and 2-3 parts of herb of hippuris vulgaris L.. The traditional Chinese medicine has the advantages that various medicines are jointly used by means of scientific compatibility, accordingly, effects of eliminating phlegm, stopping cough, removing dampness, activating blood, facilitating lungs, expelling pus and phlegm, relieving asthma, regulating qi to alleviate pain and the like can be realized, excellent bronchial asthma treatment effects can be realized, and the traditional Chinese medicine is made of simple raw materials and convenient to take.